Authors


Bassam N. Estfan, MD

Latest:

Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic Cancer

Suneel K. Kamath, MD, et al investigated exceptional responders and the correlation of nonsynonymous mutations for patients with advanced pancreatic cancer.



Peter H. O’Donnell, MD, PhD

Latest:

Emerging Data and Future Directions in UC

Experts highlight emerging data and novel regimens that have the biggest potential to impact treatment and management of patients with urothelial cancer.


Jessica Freydman, PharmD

Latest:

Expert Commentary on the Product Profile of Tepotinib

In an interview with ONCOLOGY®, David Hughes PharmD, BCOP, and Jessica Freydman, PharmD, offers a comprehensive review of real-world treatment considerations of tepotinib as therapy for patients with metastatic non–small cell lung cancer that have MET exon14 skipping mutations.






Xiaoli Mi, MD

Latest:

Cross Q&A: The Memorial Sloan-Kettering Mavericks

The Moffitt Marrowvingians take their turn questioning the Memorial Sloan Kettering Mavericks on their presented clinical trial data.



Juejing Chen, MD

Latest:

Ocular Toxicities of MEK Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis

Jing Han, MD, and colleagues examine the prevalence and characteristics of ocular toxicities associated with MEK inhibition.









Caleb W. Schroeder, MD

Latest:

Complete Pathologic Response to Neoadjuvant Chemoimmunotherapy and Oxaliplatin-Induced Fever Associated With IL-6 Release in a Patient With Locally Advanced Colon Cancer

This case presents a patient with locally advanced, unresectable, mismatch repair–deficient sigmoid colon cancer who was treated with neoadjuvant chemoimmunotherapy followed by surgical resection leading to a complete pathologic response after preoperative systemic chemoimmunotherapy.


Claudia Tellez, MD

Latest:

Importance of a Multidisciplinary Team at a Hispanic Breast Cancer Clinic

The Hispanic Breast Cancer Clinic at Northwestern Memorial Hospital includes a social worker, nurse practitioners, a medical oncologist, a radiation oncologist, and surgeons, says Claudia Tellez, MD.




Prakash Sharma, MBBS

Latest:

Danazol for the Treatment of Myelodysplastic Syndromes: A Systematic Review

Danazol was reviewed as an effective treatment option for patients with myelodyspplastic syndromes, according to a recently published article by Sangam Shah, MBBS, et al.


Raymond B. Mailhot, MD, MPH

Latest:

RT May Affect Scholastic Performance in Pediatric Brain Tumor Survivors

Raymond B. Mailhot, MD, MPH, discussed how radiation therapy can impact education and survivorship for pediatric survivors of brain tumors.


Jenna Ghazal, BSc

Latest:

Immune Modulation in Sarcoma: Targeting the Tumor Microenvironment

Explore the latest advancements in sarcoma immunotherapy, focusing on tumor microenvironment modulation and innovative treatment strategies for improved patient outcomes.


Lawrence W. Liu, MD

Latest:

CARTITUDE-4 Study: Cilta-Cel vs Standard of Care for Lenalidomide-Refractory Multiple Myeloma

Panelists review the CARTITUDE-4 study results highlighting the efficacy of cilta-cel in lenalidomide-refractory multiple myeloma, addressing implementation challenges and patient preferences in varying relapse scenarios.


Jessica Cheng, MD

Latest:

Improving Quality of Life in Cancer With Physical Medicine & Rehabilitation

Jessica Cheng, MD, highlights how physical medicine and rehabilitation may help optimize function and performance status in patients with cancer.



Julika Wirth, MD

Latest:

Value of Geriatric Assessment in Patients With Genitourinary Carcinoma

This work from Quirin Zangl, MD, and colleagues to evaluate comprehensive geriatric assessment tools to better guide patients with urogenital carcinomas perioperatively and, consequently, to intensify or reduce hospital resource use.


Ashley L. Sumrall, MD

Latest:

Dordaviprone Presents Therapeutic Option for Diffuse Midline Glioma Type

Historical standards for H3 K27M–mutant diffuse midline glioma treatment may harm healthy central nervous system cells, according to Ashley L. Sumrall, MD.